2Purnomo E, Emoto N, Nugrahaningsih DA, et al. Glycosaminogly- can overproduction in the aorta increases aortic calcification in murine chronic kidney disease. J Am Heart Assoc,2013,2 (5) : e000405. 被引量：1
3Zhu D, Mackenzie NCW, Milldn JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One,2011,6(5) :e19595. 被引量：1
4Toyosawa S,Oya K, Sato S, et al. Osteocyte and DMP1. Clin Cal- cium ,2012,22 (5) :713 - 720. 被引量：1
5Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nature Genetics ,2006,38 ( 11 ) : 1310 - 1315. 被引量：1
6Prideaux M, Loveridge N, Pitsillides AA, et al. Extracellular ma- trixmineralization promotes El l/gp38 glycoprotein expression and drives osteocyticdifferentiation. PLoS One, 2012, 7 ( 5 ) : e36786. 被引量：1
7Li X, Ominsky MS, Warmington KS, et al. Sclerostinantibodytreat- ment increases bone formation, bone mass, and bone strength ina rat model of postmenopausal osteoporosis. J Bone Miner Res, 2009,24 (4) :578 - 588. 被引量：1
8Claes K J, Viaene L, Heye S, et al. Sclerostin : Another vascular- calcification inhibitor. J Clin Endocrinol Metab, 2013,98 ( 8 ) : 3221 - 3228. 被引量：1
9Register TC, Flruska KA, Divers J, et al. Sclerostin is positivel- yassociated with bone mineral density in men and women and negativelyassociated with carotid calcified atherosclerotic plaque in men from theAfricanamerican - diabetes heart study. J Clin Endocrinol Metab,2014,99 ( 1 ) :315 - 321. 被引量：1
10Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circulation Research, 2005,97 ( 2 ) : 105 - 114. 被引量：1
